May & Baker Nig. Plc. is set to launch a new bitter leaf capsule, Rofeda.
The capsule, developed by a Nigerian professor, is to be commercialized through the company’s herbal plant in Ota.
Head of Pharma Sales and Marketing at May & Baker, Obinna Emeribe, who made this known at a news conference in Lagos, explained that the product is the result of collaboration with research centres, including the National Institute for Pharmaceutical Research and Development (NIPRD) in Abuja.
He said Rofeda, a capsule with significant health benefits, will be introduced in the Nigerian market within the next one to two months, advancing healthcare in Nigeria.
Emeribe said apart from Rofeda, the pharmaceutical firm plans to introduce at least seven new products by the end of 2024, all aimed at promoting healthy living, pointing out that the products reflect the company’s ongoing focus on research and development, cutting-edge technologies, and strategic partnerships.
May & Baker continues to partner with NIPRD, which has been instrumental in the establishment of the company’s herbal plant in Ota. The collaboration is geared toward the commercialization of medicines for managing sickle cell anemia and other health conditions.
“There are very important ingredients in the normal bitter leaf we eat that help human life. Our continued investment in research and development, our focus on harnessing cutting-edge technologies, and our commitment to collaborations and partnerships will guide us as we navigate the ever-changing landscape of healthcare,” Emeribe added.
In addition, the company is preparing to unveil a bio-vaccine manufacturing facility, a project initiated in 2005 in partnership with the Federal Government.
